Cargando…

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial

BACKGROUND: Curcumin is the main active ingredient of the spice turmeric, investigated extensively for putative anticancer properties. OBJECTIVES: This phase IIa open-labelled randomized controlled trial aimed to assess safety, efficacy, quality of life, neurotoxicity, curcuminoids, and C-X-C-motif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howells, Lynne M, Iwuji, Chinenye O O, Irving, Glen R B, Barber, Shaun, Walter, Harriet, Sidat, Zahirah, Griffin-Teall, Nicola, Singh, Rajinder, Foreman, Nalini, Patel, Samita R, Morgan, Bruno, Steward, William P, Gescher, Andreas, Thomas, Anne L, Brown, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602900/ https://www.ncbi.nlm.nih.gov/pubmed/31132111 http://dx.doi.org/10.1093/jn/nxz029

Ejemplares similares

Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial
por: Irving, Glen RB, et al.
Publicado: (2015)

Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy
por: James, Mark I., et al.
Publicado: (2015)

Ex vivo explant model of adenoma and colorectal cancer to explore mechanisms of action and patient response to cancer prevention therapies
por: Khan, Sam, et al.
Publicado: (2022)

Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin
por: Perkins, S, et al.
Publicado: (2003)

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2016)

Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration
por: Garcea, G, et al.
Publicado: (2004)

The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318
por: Breakstone, Rimini, et al.
Publicado: (2022)

Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review
por: Khan, Farheen Badrealam, et al.
Publicado: (2022)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

New Paradigms to Assess Consequences of Long-Term, Low-Dose Curcumin Exposure in Lung Cancer Cells
por: Smagurauskaite, Gintare, et al.
Publicado: (2020)

Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line
por: Hudson, E Ann, et al.
Publicado: (2003)

Folfox encephalopathy: A rare case series
por: Batra, Ullas, et al.
Publicado: (2017)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Quantitative Methods For Finance And Investments
por: Teall, John
Publicado: (2002)

Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients
por: Sugarbaker, Paul H., et al.
Publicado: (2020)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)

Prevotella contributes to individual response of FOLFOX in colon cancer
por: Hou, Xiao‐Ying, et al.
Publicado: (2021)

Safety study of Folfox-HAIC in relieving bed restriction
por: Zhao, Xiaoyun, et al.
Publicado: (2021)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Effect of 1% curcumin gel on myeloperoxidase activity in GCF and periodontal status in the initial phase of orthodontic tooth movement
por: Samita,, et al.
Publicado: (2022)

Patient-reported outcomes in PROSPECT trial (Alliance N1048) – FOLFOX is not a panacea
por: O'Cathail, Sean M., et al.
Publicado: (2023)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
por: Soon, Wai Cheong, et al.
Publicado: (2014)

FOLFOX Induced Takotsubo Cardiomyopathy Treated with Impella Assist Device
por: Sundaravel, Swethika, et al.
Publicado: (2017)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
por: Okada, Shunji, et al.
Publicado: (2017)

Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4
por: Qin, Shukui, et al.
Publicado: (2017)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Hou, Xiaoying, et al.
Publicado: (2021)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
por: Moser, Tina, et al.
Publicado: (2020)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
por: Powell, Erin D., et al.
Publicado: (2009)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
por: Faure, Marjorie, et al.
Publicado: (2017)

Identification of the predictive genes for the response of colorectal cancer patients to FOLFOX therapy
por: Lin, Hengjun, et al.
Publicado: (2018)

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jbf0lruusss45mekr7j71qtrpk